--- title: "Alto Neuroscience (NYSE:ANRO) Trading 8% Higher Following Earnings Beat" type: "News" locale: "en" url: "https://longbridge.com/en/news/295819442.md" description: "Alto Neuroscience (NYSE:ANRO) shares rose 8% after reporting an EPS of ($0.65), beating estimates of ($0.73). Analysts adjusted price targets, with BTIG raising its to $37.00 and Wedbush to $26.00. Institutional investors including Northwestern Mutual and Commodore Capital increased their stakes in the first quarter. The stock currently holds a 'Moderate Buy' consensus rating with an average target of $36.62." datetime: "2026-08-13T15:20:35.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/295819442.md) - [en](https://longbridge.com/en/news/295819442.md) - [zh-HK](https://longbridge.com/zh-HK/news/295819442.md) generator: "portal-rs" --- # Alto Neuroscience (NYSE:ANRO) Trading 8% Higher Following Earnings Beat Alto Neuroscience, Inc. (NYSE:ANRO - Get Free Report)'s share price shot up 8% during mid-day trading on Thursday following a stronger than expected earnings report. The company traded as high as $31.83 and last traded at $31.5170. 91,789 shares changed hands during trading, a decline of 75% from the average session volume of 363,648 shares. The stock had previously closed at $29.18. Get **Alto Neuroscience** alerts: The company reported ($0.65) earnings per share for the quarter, topping the consensus estimate of ($0.73) by $0.08. ## Analyst Ratings Changes A number of research firms recently weighed in on ANRO. Wedbush upped their price target on Alto Neuroscience from $24.00 to $26.00 and gave the stock a "neutral" rating in a report on Thursday. HC Wainwright reiterated a "buy" rating on shares of Alto Neuroscience in a research report on Wednesday, June 17th. BTIG Research upped their price target on shares of Alto Neuroscience from $28.00 to $37.00 and gave the company a "buy" rating in a report on Thursday. Wolfe Research began coverage on shares of Alto Neuroscience in a research note on Friday, May 22nd. They issued an "outperform" rating for the company. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Alto Neuroscience in a research note on Wednesday, July 29th. Eight research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $36.62. **Get Our Latest Analysis on ANRO** ## Hedge Funds Weigh In On Alto Neuroscience Several institutional investors and hedge funds have recently bought and sold shares of the stock. Northwestern Mutual Wealth Management Co. increased its holdings in shares of Alto Neuroscience by 14,567.0% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 212,672 shares of the company's stock worth $3,786,000 after buying an additional 211,222 shares during the last quarter. Jennison Associates LLC acquired a new position in Alto Neuroscience in the first quarter valued at $8,687,000. Y Intercept Hong Kong Ltd purchased a new stake in Alto Neuroscience during the first quarter valued at about $538,000. Commodore Capital LP grew its position in Alto Neuroscience by 49.4% during the first quarter. Commodore Capital LP now owns 2,723,196 shares of the company's stock valued at $61,217,000 after acquiring an additional 900,000 shares during the period. Finally, Orbimed Advisors LLC increased its stake in Alto Neuroscience by 34.0% during the first quarter. Orbimed Advisors LLC now owns 167,500 shares of the company's stock worth $3,765,000 after acquiring an additional 42,500 shares during the last quarter. ## Alto Neuroscience Price Performance The company has a market capitalization of $1.13 billion, a price-to-earnings ratio of -13.24 and a beta of 1.06. The company has a quick ratio of 20.52, a current ratio of 20.52 and a debt-to-equity ratio of 0.07. The company has a 50 day simple moving average of $25.44 and a 200 day simple moving average of $22.57. ## Alto Neuroscience Company Profile (Get Free Report) Alto Neuroscience NYSE: ANRO is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression. Alto's proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies. ## Further Reading - Five stocks we like better than Alto Neuroscience - Axos Financial Keeps Proving the Digital Banking Model Works - SpaceX’s First Earnings Report Only Made Wall Street More Divided - Plug Power Charges Ahead: Margin Expansion Sparks a Rally - Abercrombie’s Comeback Is a Work in Progress *This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.* Continue following MarketBeat Add MarketBeat as your preferred source on Google to see our latest stories in your feed. Add As Preferred Source ## Should You Invest $1,000 in Alto Neuroscience Right Now? Before you consider Alto Neuroscience, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alto Neuroscience wasn't on the list. While Alto Neuroscience currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [ANRO.US](https://longbridge.com/en/quote/ANRO.US.md) - [AX.US](https://longbridge.com/en/quote/AX.US.md) - [PLUG.US](https://longbridge.com/en/quote/PLUG.US.md) - [ANF.US](https://longbridge.com/en/quote/ANF.US.md) - [PLUN.DE](https://longbridge.com/en/quote/PLUN.DE.md) ## Related News & Research - [Bank of New York Mellon Corp Purchases Shares of 76,330 Alto Neuroscience, Inc. $ANRO](https://longbridge.com/en/news/298414990.md) - [Alto Neuroscience Announces Participation in Upcoming Investor Conferences | ANRO Stock News](https://longbridge.com/en/news/298456017.md) - [Northwestern Mutual Wealth Management Co. Sells 76,868 Shares of Cue Biopharma, Inc. $CUE](https://longbridge.com/en/news/298427697.md) - [Northwestern Mutual Wealth Management Co. Cuts Stake in Waste Connections, Inc. $WCN](https://longbridge.com/en/news/298128514.md) - [Northwestern Mutual Wealth Management Co. Sells 1,061 Shares of AutoZone, Inc. $AZO](https://longbridge.com/en/news/298015308.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**